Peter Gaszner

Summary

Affiliation: Plant Protection Institute
Country: Hungary

Publications

  1. ncbi request reprint [Clinical observations with aripiprazole in schizophrenia]
    Peter Gaszner
    Orszagos Pszichiatriai es Neurologiai Intezet
    Neuropsychopharmacol Hung 8:29-32. 2006
  2. ncbi request reprint [Complex therapy of schizophrenia]
    Peter Gaszner
    SE Pszichiatriai es Pszichoterapias Klinika
    Neuropsychopharmacol Hung 11:41-5. 2009
  3. ncbi request reprint Clozapine maintenance therapy in schizophrenia
    Peter Gaszner
    National Institute of Psychiatry and Neurology, 1021, Budapest, Huvosvolgyi u 116, Hungary
    Prog Neuropsychopharmacol Biol Psychiatry 28:465-9. 2004
  4. ncbi request reprint Major depression and the synthetic enhancer substances, (-)-deprenyl and R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane
    Peter Gaszner
    National Institute of Psychiatry and Neurology, H 1021 Huvösvölgyi út 116, Budapest, Hungary
    Prog Neuropsychopharmacol Biol Psychiatry 30:5-14. 2006
  5. ncbi request reprint Agranulocytosis during clozapine therapy
    Peter Gaszner
    National Institute of Psychiatry and Neurology, Budapest, Hungary
    Prog Neuropsychopharmacol Biol Psychiatry 26:603-7. 2002
  6. ncbi request reprint The use of the synthetic enhancer substances (-)-deprenyl and (-)-BPAP in major depression
    Peter Gaszner
    National Institute of Psychiatry and Neurology, Budapest, Hungary
    Neuropsychopharmacol Hung 6:210-20. 2004
  7. ncbi request reprint [About the curability of schizophrenia]
    Peter Gaszner
    Orszagos Pszichiatriai es Neurologiai Intezet, Budapest
    Neuropsychopharmacol Hung 7:39-42. 2005
  8. ncbi request reprint Comparison between genes of Alzheimer's disease and brain tissue of others
    Peter Gaszner
    National Institute of Neurology and Psychiatry, Budapest, Hungary
    Neuropsychopharmacol Hung 8:211-4. 2006
  9. ncbi request reprint About the menopausal depression
    Peter Gaszner
    National Institute of Psychiatry and Neurology, Budapest, Hungary
    Neuropsychopharmacol Hung 7:208-14. 2005
  10. ncbi request reprint [Pharmacovigilance as new direction of research]
    Gabor Gaszner
    Orszagos Pszichiatriai es Neurologiai Intezet, Budapest
    Neuropsychopharmacol Hung 7:194-8. 2005

Collaborators

Detail Information

Publications10

  1. ncbi request reprint [Clinical observations with aripiprazole in schizophrenia]
    Peter Gaszner
    Orszagos Pszichiatriai es Neurologiai Intezet
    Neuropsychopharmacol Hung 8:29-32. 2006
    ..The patients had good compliance with aripiprazol...
  2. ncbi request reprint [Complex therapy of schizophrenia]
    Peter Gaszner
    SE Pszichiatriai es Pszichoterapias Klinika
    Neuropsychopharmacol Hung 11:41-5. 2009
    ..Fields of indication: first psychotic episode, acut schizophrenic exacerbation, chronic schizophrenia, the treatment of behavior disorder in dementia, maniac phase of bipolar disorder, treatment of behavioral disorders...
  3. ncbi request reprint Clozapine maintenance therapy in schizophrenia
    Peter Gaszner
    National Institute of Psychiatry and Neurology, 1021, Budapest, Huvosvolgyi u 116, Hungary
    Prog Neuropsychopharmacol Biol Psychiatry 28:465-9. 2004
    ..Compliance is good; schizophrenic patients are willing to take this atypical antipsychotic for years on end. Clozapine treatment is associated with a low relapse rate and a favorable safety profile...
  4. ncbi request reprint Major depression and the synthetic enhancer substances, (-)-deprenyl and R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane
    Peter Gaszner
    National Institute of Psychiatry and Neurology, H 1021 Huvösvölgyi út 116, Budapest, Hungary
    Prog Neuropsychopharmacol Biol Psychiatry 30:5-14. 2006
    ....
  5. ncbi request reprint Agranulocytosis during clozapine therapy
    Peter Gaszner
    National Institute of Psychiatry and Neurology, Budapest, Hungary
    Prog Neuropsychopharmacol Biol Psychiatry 26:603-7. 2002
    ..These adverse reactions were recognized early and the appropriate treatment of agranulocytosis resulted in complete recovery in both cases...
  6. ncbi request reprint The use of the synthetic enhancer substances (-)-deprenyl and (-)-BPAP in major depression
    Peter Gaszner
    National Institute of Psychiatry and Neurology, Budapest, Hungary
    Neuropsychopharmacol Hung 6:210-20. 2004
    ....
  7. ncbi request reprint [About the curability of schizophrenia]
    Peter Gaszner
    Orszagos Pszichiatriai es Neurologiai Intezet, Budapest
    Neuropsychopharmacol Hung 7:39-42. 2005
    ..His compliance has been perfect, clozapine has no side effects...
  8. ncbi request reprint Comparison between genes of Alzheimer's disease and brain tissue of others
    Peter Gaszner
    National Institute of Neurology and Psychiatry, Budapest, Hungary
    Neuropsychopharmacol Hung 8:211-4. 2006
    ..Silver staining was performed on some samples and 5 of 7 samples tested from one donor diagnosed with Alzheimer's like dementia showed evidence of Alzheimer's disease by this method...
  9. ncbi request reprint About the menopausal depression
    Peter Gaszner
    National Institute of Psychiatry and Neurology, Budapest, Hungary
    Neuropsychopharmacol Hung 7:208-14. 2005
    ..But the other changing reproductive physiology, as progesterone, inhibin level, CNS activity of gonadal steroids may have role in depression during menopause...
  10. ncbi request reprint [Pharmacovigilance as new direction of research]
    Gabor Gaszner
    Orszagos Pszichiatriai es Neurologiai Intezet, Budapest
    Neuropsychopharmacol Hung 7:194-8. 2005
    ..We review how the danger of polypharmacy can be avoided by reducing the dose of the current drug; by using therapeutic drug; or just by monitoring therapeutic and adverse effects...